Platelet activating factor antagonists interact with GABA(A) receptors

L. G. Miller, N. G. Bazan, R. B. Roy, F. Clostre, A. Gaver, P. Braquet

Research output: Contribution to journalArticlepeer-review


Platelet activating factor (PAF) is ubiquitous in mammals, and may have multiple functions in the central nervous system. Triazolobenzodiazepine compounds are active both at the GABA(A) receptor and as PAF antagonists. To investigate whether PAF antagonist activity is involved in the actions of triazolobenzodiazepines, we examined effects of two nonbenzodiazepine PAF antagonists on binding and function at the GABA(A) receptor. The gingkolide terpene, BN 52021 and the dioxolane-based compound BN 52115 had no effect on benzodiazepine binding or chloride channel binding in cortical membrane preparations. However, chloride uptake into cortical synaptoneurosomes was enhanced with 1 uM BN 52021 but not 1 uM BN 52115. The effect of BN 52021 was prevented by 1 uM flumazenil. PAF antagonists appear to augment GABA(A) receptor function without affecting binding.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalResearch Communications in Chemical Pathology and Pharmacology
Issue number2
StatePublished - 1991
Externally publishedYes


Dive into the research topics of 'Platelet activating factor antagonists interact with GABA(A) receptors'. Together they form a unique fingerprint.

Cite this